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The prediction, diagnosis and management
of complications in monochorionic twin
pregnancies: the OMMIT (Optimal
Management of Monochorionic Twins)
study
Fiona L. Mackie1,2, R. Katie Morris1,2 and Mark D. Kilby1,2*
Abstract
Background: Monochorionic twin pregnancies are at increased risk of complications due to sharing a single
placenta and potentially developing unbalanced vascular anastomoses. Complications include twin-twin transfusion
syndrome (TTTS) which affects 10–15% monochorionic twins, and if untreated has a 70–90% perinatal loss rate. We are
currently unable to predict which twins will develop complications or to what severity. We have previously shown
differences in angiogenic and placental growth factors in maternal blood in pregnancies complicated by TTTS
compared to twin pregnancies not complicated by TTTS but matched for gestation. There is also evidence to
suggest that abnormal ultrasound measurements recorded in the first trimester (nuchal translucency and crown-rump
length) may be associated with severe TTTS later in pregnancy, however the detection rate is only reported as 52%. We
hypothesize that if these changes precede the development of the clinical syndrome, this may increase the sensitivity
and specificity of detecting adverse pregnancy outcomes.
Methods: This cohort study has retrospective and prospective elements. In the retrospective cohort we will measure
factors (decided based on preliminary work and a systematic review and meta-analysis) in stored maternal
blood samples taken in the first-trimester, extract first-trimester ultrasound measurements and match these to
pregnancy outcome. The prospective cohort will be divided into a “screening” cohort and “complicated” cohort. The
screening cohort will undergo serial maternal blood sampling at 12, 16 and 20 weeks; we will extract ultrasound
measurements and match to pregnancy outcome. The complicated cohort will comprise of women referred to
the Fetal Medicine Centre with complications of monochorionicity. If the decision is taken to undergo fetoscopic
laser ablation we will take maternal blood samples and amniotic fluid samples pre- and post-laser treatment. The
same factors will be measured in the prospective cohort as informed by the retrospective study.
Discussion: This study aims to increase knowledge surrounding the pathology of complications in monochorionic twins,
to aid future diagnosis and management.
Trial registration: ISRCTN 13114861 (retrospectively registered)
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Background
All twin pregnancies have increased risk over singletons,
with monochorionic (MC) twins demonstrating the
highest risk. Thirty per cent of twins are MC, but they
experience 75% of all twin complications, the patholo-
gies of which are closely linked to the fact that they
share a single placenta and thus can develop unbalanced
vascular anastomoses [1]. Complications that are specific
to monochorionicity include twin-twin transfusion syn-
drome (TTTS), selective intrauterine growth restriction
(sIUGR) and twin anaemia polycythaemia sequence
(TAPS) [2]. TTTS complicates 10–15% of MC twins and
usually occurs between 15 and 26 weeks. At present, the
prognosis is dependent upon early treatment and method
of treatment: if untreated it is associated with a perinatal
loss rate of 70–90%. A staging system, the Quintero
system, exists but correlates poorly with outcome [3].
Even with apparently ‘successful’ antenatal treatment (with
fetoscopic laser ablation (FLA)), TTTS is still associated
with 10% neurological morbidity. We are currently unable
to accurately predict which twins will develop complica-
tions or how severe they will be. There is some evidence
that first trimester ultrasound screening of MC twin preg-
nancies between 11 and 13+6 weeks may predict adverse
pregnancy outcome. These ultrasound features include: a)
discordance in fetal nuchal translucency thickness (NT)
with an increase in the recipient fetus [4, 5] and b) dis-
cordance in fetal crown rump length (CRL) measurements
between the MC twins [5]. Although ultrasonographic fea-
tures have a reasonable sensitivity and specificity in terms
of allocating risk of severe TTTS, such screening is still
associated with a significant false positive and false
negative rate as the detection rate is only 52% [6].
We have recently reported significant differences in
maternal serum between women with twin pregnancies
complicated by TTTS, and twin pregnancies not compli-
cated by TTTS but matched for gestational age [7]. These
differences were seen in alpha-fetoprotein (αFP), β-hCG,
plasma vascular endothelial growth factor (VEGF)-C,
angiopoietin (Ang)-2 levels and the ratio of soluble vascu-
lar endothelial growth factor receptor-1 (sVEGFR-1) (also
known as soluble fms-like tyrosine kinase-1. [sFlt-1]) to
placental growth factor (PlGF) levels. We hypothesize that
if these changes precede the development of the clinical
syndrome, this may increase the sensitivity and specificity
of detecting adverse pregnancy outcomes. The objective
of this paper is to describe the aims and study design of
our ongoing platform of work exploring complications in
MC twin pregnancies.
Methods
Aims of study
The aim of our research is to improve knowledge of
complications in MC twin pregnancies, and incorporate
this knowledge into a predictive model in the future.
Specifically we will investigate:
1. If abnormal first-trimester ultrasound measurements
(NT and CRL) are associated with the development
of complications later in pregnancy.
2. The effects that these complications and their
treatment have on:
a. angiogenic factors in maternal serum/plasma
b. placental growth factors in maternal serum/plasma
c. angiogenic factors in amniotic fluid
d. placental growth factors in amniotic fluid
Study design
This cohort study has both retrospective and prospective
elements. There will be 1 retrospectively recruited first-
trimester cohort, 1 prospectively recruited “screening”
cohort, and 1 prospectively recruited “complicated”
cohort. In all aspects of the work monochorionicity must
have been confirmed using the ‘T’ sign on first-trimester
ultrasound scan.
Retrospective cohort
We will initially perform a retrospective study of stored
maternal serum microbiology samples and Down Syn-
drome screening samples taken in the first trimester
from MC twin pregnancies as part of routine booking at
Birmingham Women’s NHS Foundation Trust. These
samples are routinely stored for 2 years in the microbiol-
ogy and clinical chemistry department, and equate to
approximately 170 samples. We will measure maternal
angiogenic factors and placental growth factors in these
samples, collect first trimester ultrasound measurements
(CRL and NT) and patient characteristics and pregnancy
outcome data. As Down Syndrome screening samples
are received from 31 sites in the UK, we will ask clini-
cians at these sites to assist in data collection using a
pre-designed proforma. Where clinicians feel unable to
help with data collection, we will visit the sites and
collect the outcomes ourselves. The primary outcome
will be whether participants developed a complication in
pregnancy (TTTS, TAPS, sIUGR, single or double intra-
uterine demise) and the severity of these complications.
Secondary outcomes will include delivery (gestation at
delivery, mode of delivery, birth weight, condition of
twins at delivery) and neonatal outcomes (admission to
neonatal unit, diagnosis of comorbidity, particularly
neurological). The maternal angiogenic factors and pla-
cental growth factors measured will be decided based
on our preliminary work (see above) and a systematic
review and individual patient data (IPD) meta-analysis
(see PROSPERO CRD42015024975 for full protocol).
As this is a retrospective study and the results of our
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study will not affect patient care, patients whose
blood samples we are using in this retrospective study
will not be consented or informed of the results.
However, all women under the care of Birmingham
Women’s NHS Foundation Trust are aware that the
hospital is research active, and that their blood sam-
ples may be used in this way, and are given the
option of opting out if they so wish. Samples from
patients who have indicated that they do not want
their samples to be used for research will be excluded
from this study. This retrospective study will inform
the subsequent prospective study.
Prospective cohort
The prospective study will run over 2 years (August 2015–
August 2017) and there will be 2 cohorts: a “screening”
MC twin cohort (Cohort S), and a cohort who have
developed complications (Cohort C) (see Fig. 1). In both
cohorts, informed written consent will be obtained. The
“screening” cohort (Cohort S) will be approached in the
‘multiples’ antenatal clinic where all twin pregnancies are
managed at Birmingham Women’s NHS Foundation
Trust. We will ask participants with confirmed MC twin
pregnancies to consent to 2 extra bottles of blood being
taken during their routine Down Syndrome blood test or
Fig. 1 OMMIT-2 Prediction of adverse outcome in MC twins: prospective study
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booking blood tests, and for permission to record their
first trimester ultrasound measurements, and access the
above outcome data as specified in the retrospective study.
We will then repeat the blood sampling at 16 weeks and
20 weeks gestation when they attend for routine ultra-
sound scans. If the participant does not develop any com-
plications, this will be the end of her involvement in the
study and we will just collect the outcome data. However,
if she develops a complication (e.g. TTTS, TAPS, sIUGR,
single intrauterine demise) she will be invited and
consented to enter the second prospective “complicated”
cohort.
Women who develop complications are referred to the
West Midlands Fetal Medicine Centre. The second
cohort (Cohort C) will have serial maternal blood tests
performed (pre-FLA and 6 h post-FLA) looking at the
biomarkers informed by the IPD meta-analysis and
retrospective study. A small amniotic fluid sample will
be collected pre-FLA when the port for the fetoscope
has been inserted into the recipient sac in the uterus,
and a second small sample taken post-FLA when the
ablation has been completed. The recipient twin will
have polyhydramnios as it is part of the diagnostic
criteria for TTTS, and it is routine clinical practice to
perform amnioreduction at this point. All samples
(serum and amniotic fluid) will be spun down, aliquoted,
frozen and stored at−80° Celsius. We will assess the
same factors in the amniotic fluid as in the maternal
serum. Data will be collected on the ultrasound scans
performed as part of routine clinical management of
these conditions, as will pregnancy outcome data. Quintero
staging will be used to classify TTTS [8].
Expected number of participants
In the retrospective study cohort, these samples are
routinely stored for 2 years and equate to approximately
170 samples in total.
Regarding the prospective cohort S: Birmingham
Women’s NHS Foundation Trust has 7,900 deliveries
per annum, approximately 2% of all maternities are
multiple pregnancies and thus would equate to 158
maternities per annum. Of these, approximately 30% are
MC twins (47 MC twins per annum) and 70% of women
with an MC pregnancy will consent to Down syndrome
screening (33 MC twins per annum). If we propose that
5 per year will be lost by miscarriage or decline partici-
pation in the study, then we predict recruitment of
approximately 28 MC twin pregnancies per annum,
which equates to 56 maternities over 2 years of proposed
recruitment.
At the West Midlands Fetal Medicine Centre we
treat approximately 40–60 women a year with TTTS,
which equates to 80–120 women over 2 years. If we
allow for a 50% recruitment rate and incomplete
follow-up, results in 40–60 sets of parents participat-
ing over 2 years in cohort C.
Data management and data analyses
At recruitment, each participant will receive a unique
study identifier to allow linkage of data. Data will be
collected using a purposely designed proforma (as per
the retrospective cohort) and manually input onto a
secure electronic database. Hard-copies of data will be
kept in a locked filing cabinet, in a swipe-card access
department at Birmingham Women’s NHS Foundation
Trust. We will ensure that we remain compliant with
the Trust’s Information Governance policies at all times.
Descriptive data will be reported. First trimester ultra-
sound measurements (NT and CRL) and serial serum
biomarkers will be compared between participants in
cohort S who go on to develop complications, and
participants in cohort S who do not develop complica-
tions. The serum biomarker results from the 16 and 20
week blood samples from participants in cohort S will
also act as the control group for cohort C participants.
Additionally serum and amniotic fluid biomarkers will
be compared longitudinally (i.e. pre- and post-FLA) for
each participant in cohort C, to evaluate the potential
effect of FLA on the biomarkers. The appropriate statis-
tical tests will be used. Chi-squared will be used for cat-
egorical variables, and student’s t-test (paired and unpaired
where appropriate) for continuous variables. Logistic
regression models will be created to assess the association
between variables and outcomes and presented as odds
ratios (OR) with a 95% confidence interval (CI). Different
cut-offs will be used for TTTS (Quintero staging) and
sIUGR (EFW <10th centile, <5th centile).
Discussion
This study aims to increase knowledge surrounding the
pathology of complications in MC twins, which in turn
is hoped to aid future diagnosis and management. To
our knowledge, this is the first study to look at these
serum and amniotic fluid biomarkers in such a large
cohort of MC twin pregnancies.
Although we are one of the largest Fetal Medicine
Centres in the UK, the number of participants eligible
for inclusion is insufficient to power the development of
a prediction model, and may cause false negative results.
The results of this study may inform a larger, multi-
centre study to be conducted over several years so as to
create a prediction model to triage MC twin pregnancies
as high-risk or low-risk for complications, and thus
requiring more or less surveillance antenatally.
There will be some women who will have booked at
Birmingham Women’s NHS Foundation Trust and will
be recruited to both the first-trimester screening cohort
and the “complicated” cohort. Parents are routinely
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informed of the potential complications of MC preg-
nancy at booking, and by seeing these women in the
first-trimester, this will give us the opportunity to inform
them of the second part of the prospective study and
they will have at least 4 weeks to consider participation
should a complication develop. However, as a tertiary
Fetal Medicine Centre we receive a lot of referrals from
around the UK for second opinions and to perform
treatment for MC twin complications, e.g. FLA. These
referred patients will also be eligible for inclusion in the
“complicated” cohort, although we will not have first-
trimester blood samples for them. Unfortunately, due to
the rapid progression of complications, these parents
may have a limited time to consider participation. How-
ever, this is still in-keeping with ethical approval.
Although we will be unable to gain consent for partici-
pants in the retrospective study, we intend to publish
our results on the TAMBA website to which the public
have access. We also hope to present them at inter-
national conferences and publish in leading medical
journals.
We expect to lose some participants to follow-up, and
to be unable to collect outcome data for some patients
who may have moved areas, or have had their baby(ies)
transferred out to different neonatal units.
Conclusions
This study hopes to increase knowledge of the patho-
logical processes involved in the continuum of MC twin
complications, and allow us to predict which MC twins
will develop complications so that we are better able to
target surveillance and therapy, and ultimately improve
outcomes for these families.
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